CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “CELL-FREE TUMOR DNA AND NEUTROPHIL EXTRACELLULAR TRAPS AS NOVEL THERAPEUTIC TARGETS FOR PANCREATIC CANCER” at the Frontiers in Cancer Immunotherapy organized by the New York Academy of Sciences May 14-15, 2019, in New York, New York.
Dr. Tetz’s presentation provided an overview of CLS-014, an engineered gene therapy platform addressing unmet need in pancreatic cancer with multiple follow-up extension opportunities. CLS-014 is an AAV vector that targets cell-free DNA, and has the potential for the treatment of solid tumors. The poster presentation also provided an overview of in vivo animal efficacy evaluating CLS-014 for the treatment of pancreatic cancer.
Poster Session Presentation Details:
- Title: Cell-Free Tumor DNA And Neutrophil Extracellular Traps As Novel Therapeutic Targets For Pancreatic Cancer
- Poster Number: 26
- Event: Frontiers in Cancer Immunotherapy (NYAS)
- Date: Thursday, May 14-15, 2019
- Event Website: https://www.nyas.org/events/2019/cancer-metabolism-and-signaling/
About the CLS Therapeutics:
CLS Translating the new biology of cell-free DNA into novel therapeutic approaches for multiple cancers, beginning with our first program for pancreatic cancer. PC is the third-leading cause of cancer deaths in the United State with over 45,000 dying in 2018. It is expected to become the leading cause of cancer mortality already by 2030. 1-year survival is less than 30%. 5-year survival is less than 8%.
CLS-014 is in silico designed AAV-based vector encoding hyperactive human DNase I transgene cassette. Intravenous injection of the vector with a liver specific promoter leads to long term increase of serum DNase I activity that cleaves cell-free DNA in the blood and therefore affecting primary tumor growth, metastasis and complications associated with NETosis.
CLS-014 is administered as a single injection with any first-line chemotherapeutic agents.
CLS-Therapeutics presented animal data demonstrating the efficacy of CLS-014 in the treatment of orthotopic pancreatic mouse xenograft model. CLS-014 alone, inhibited primary tumor growth and metastasis and potentiates nab-paclitaxel.
About CLS Therapeutics Inc.
CLS-Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused to deliver on the promise of circulating nucleic acid science to advance a new generation of transformative gene therapies for cancer patients.
NEW YORK, NY / April 06, 2021 / CLS Therapeutics, cancer gene therapy company utilizing a novel therapeutic target, announces presentation at the upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting.
CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Cancer Metabolism and Signaling organized by the New York Academy of Sciences May 9, 2019, in New York, New York.
NEW YORK, NY / April 08, 2020 / CLS Therapeutics, a privately held anticancer gene therapy platform company addressing a novel therapeutic target, announces presentation at the upcoming 2020 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting that will be held from April 29 to May 2, 2019 that is planned to be held May 12 – May 15, 2020, at the Hynes Convention Center in Boston, USA.